header logo image


Page 966«..1020..965966967968..980990..»

Stem cell advance brings bioengineered arteries closer to reality – Medical Xpress

July 11th, 2017 9:48 am

July 10, 2017 Arterial endothelial cells derived from human pluripotent stem cells express activated NOTCH1 (in red, which is an arterial endothelial cell marker) and CD144 (in white, which is a pan endothelial cell marker). Credit: The Morgridge Institute for Research

Stem cell biologists have tried unsuccessfully for years to produce cells that will give rise to functional arteries and give physicians new options to combat cardiovascular disease, the world's leading cause of death.

But new techniques developed at the Morgridge Institute for Research and the University of Wisconsin-Madison have produced, for the first time, functional arterial cells at both the quality and scale to be relevant for disease modeling and clinical application.

Reporting in the July 10 issue of the journal Proceedings of the National Academy of Sciences (PNAS), scientists in the lab of stem cell pioneer James Thomson describe methods for generating and characterizing arterial endothelial cellsthe cells that initiate artery developmentthat exhibit many of the specific functions required by the body.

Further, these cells contributed both to new artery formation and improved survival rate of mice used in a model for myocardial infarction. Mice treated with this cell line had an 83 percent survival rate, compared to 33 percent for controls.

"The cardiovascular diseases that kill people mostly affect the arteries, and no one has been able to make those kinds of cells efficiently before," says Jue Zhang, a Morgridge assistant scientist and lead author. "The key finding here is a way to make arterial endothelial cells more functional and clinically useful."

Cardiovascular disease accounts for one in every three deaths each year in the United States, according to the American Heart Association, and claim more lives each year than all forms of cancer combined. The Thomson lab has made arterial engineering one of its top research priorities.

The challenge is that generic endothelial cells are relatively easy to create, but they lack true arterial properties and thus have little clinical value, Zhang says.

The research team applied two pioneering technologies to the project. First, they used single-cell RNA sequencing to identify the signaling pathways critical for arterial endothelial cell differentiation. They found about 40 genes of optimal relevance. Second, they used CRISPR-Cas9 gene editing technology that allowed them to create reporter cell lines to monitor arterial differentiation in real time.

"With this technology, you can test the function of these candidate genes and measure what percentage of cells are generating into our target arterial cells," says Zhang.

The research group developed a protocol around five key growth factors that make the strongest contributions to arterial cell development. They also identified some very common growth factors used in stem cell science, such as insulin, that surprisingly inhibit arterial endothelial cell differentiation.

"Our ultimate goal is to apply this improved cell derivation process to the formation of functional arteries that can be used in cardiovascular surgery," says Thomson, director of regenerative biology at Morgridge and UW-Madison professor of cell and regenerative biology. "This work provides valuable proof that we can eventually get a reliable source for functional arterial endothelial cells and make arteries that perform and behave like the real thing."

Thomson's team, along with many UW-Madison collaborators, is in the first year of a seven-year project supported by the National Institutes of Health (NIH) on the feasibility of developing artery banks suitable for use in human transplantation.

In many cases with vascular disease, patients lack suitable tissue from their own bodies for use in bypass surgeries. And growing arteries from an individual patient's stem cells would be cost prohibitive and take too long to be clinically useful.

The challenge will be not only to produce the arteries, but find ways to insure they are compatible and not rejected by patients.

"Now that we have a method to create these cells, we hope to continue the effort using a more universal donor cell line," says Zhang. The lab will focus on cells banked from a unique population of people who are genetically compatible donors for a majority of the population.

Explore further: Exposure to cardiovascular risk factors linked with arterial distensibility in adolescence

More information: Jue Zhang el al., "Functional characterization of human pluripotent stem cell-derived arterial endothelial cells," PNAS (2017). http://www.pnas.org/cgi/doi/10.1073/pnas.1702295114

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Excerpt from:
Stem cell advance brings bioengineered arteries closer to reality - Medical Xpress

Read More...

Rancho Cordova’s Cesca Therapeutics acquiring Sacramento-based SynGen – Sacramento Business Journal

July 11th, 2017 9:47 am

Sacramento Business Journal
Rancho Cordova's Cesca Therapeutics acquiring Sacramento-based SynGen
Sacramento Business Journal
Rancho Cordova-based regenerative medicine company Cesca Therapeutics Inc. is acquiring SynGen Inc., a Sacramento-based developer of cellular processing technology. Under the deal, SynGen's assets will be folded into Cesca (Nasdaq: KOOL) ...
Cesca Therapeutics subsidiary acquires assets of Sacramento's SynGen Inc.Sacramento Bee
Cesca Therapeutics Acquires the Cell Processing Systems of SynGen Under Asset Acquisition AgreementNasdaq
Big Move for Cesca Therapeutics Inc (NASDAQ:KOOL)StockNewsUnion

all 20 news articles »

See the rest here:
Rancho Cordova's Cesca Therapeutics acquiring Sacramento-based SynGen - Sacramento Business Journal

Read More...

Regenerating the Body With Stem Cells Hype or Hope? – Labiotech.eu (blog)

July 11th, 2017 9:47 am

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding.

The overall stem cell therapy field has failed today to show a very clear cut clinical benefit, told me Georges Rawadi, VP for Business Development at Celyad. The field now needs some significant success to attract attention.

Even though investors prefer placing their bets on the hot T cell therapies these days, some stem cell technologies such as iPSCs are starting to get traction as big industry players are exploring the territory. Last year, Bayer and Versant threw $225M into the pot to launch BlueRock Therapeutics, a regenerative medicine company that plans to develop iPSC-based therapies. A year before, Fujifilm spent $307M to acquire the iPSC company Cellular Dynamics.

Although a big success story is still lagging behind, recent advances in the field argue that stem cells indeed have the potential to translate into effective therapies for currently intractable diseases. Heres an overview of what biotechs stem cells are up to!

Stem cell treatment is not a new concept hematopoietic stem cells (HSCs) were described as early as the 1960s and bone marrow transplants have been used to treat blood cancer for decades.

The reason that we get excited about stem cell therapies comes from our experience with the hematopoietic stem cells. If you want to see what a mature stem cell therapy is like, you only need to look at bone marrow transplantation explained James Peyer, Managing Partner at Apollo Ventures, who has a Ph.D. in stem cell biology.

According to Peyer, the hematopoietic stem cell field is one of the most active areas in the stem cell world right now, mainly fueled by our advances in the gene editing space. Tools like CRISPR and TALEN allow for the genetic modification of a patients own bone marrow stem cells, which can then be expanded and returned to the patient for the correction of a genetic defect.

Last year, regulators gave green light to one of the first therapies of this kind. Strimvelis, developed by GSK, consists of an ex vivo stem cell gene therapy to treat patients with the very rare type of Severe Combined Immunodeficiency (SCID). Using the patients own cells avoids the risk of graft versus host disease (GvHD), which still affects around 30% of people receiving a bone marrow transplant.

Small wonder that the CRISPR companies, CRISPR Therapeutics, Editas, and Intellia are all active in this field, with preclinical programs in a number hematological diseases.

To date, the most prominent stem cells in the clinic are mesenchymal stem cells (MSCs), which are moving through more than 300 registered clinical trials for a wide array of diseases. These cells are able to form a variety of tissues including bone, cartilage, muscle or fat, and can be readily harvested from patients or donors for use in autologous or allogeneic therapies.

While MSCs have deluded the biotech scene with good safety profiles in clinical trials, their actual regenerative potential remains controversial, and there have been a great number of clinical failures, which many blame on a lack of demonstrated mechanisms of action.

As Peyer explained, The problem here is that, as opposed to other adult stem cells, the MSC has been unclearly defined. We know roughly what it does but we dont fully understand the molecular mechanisms driving these cells. On top of being unclearly defined, the regenerative powers of MSCs have been massively over-claimed in the past.

Another reason for the lack of clinical benefit has also been attributed to the use of undifferentiated MSCs, as Rawadi explained to me. The Belgian biotech Celyad, which has been pioneering cell therapy in the cardiovascular space, is using bone-marrow derived autologous MSCs and differentiates them into cardiomyocyte precursors to produce new heart muscle in patients with heart failure.

Although the company missed its primary endpoint in a phase III trial last year, Celyad has staked out a patient subpopulation that showed significant improvement. Its technology still has the confidence of the FDA, which just handed out a Fast Track designation and Celyad is now planning a refined Phase III trial.

One of Celyads major competitors, Australian Mesoblast, is forging ahead using allogeneic MSCs with Phase III programs in heart failure, chronic low back pain (CLBP) due to disc degeneration, as well as a range of inflammatory conditions including GvHD and rheumatoid arthritis.

Although the ability of MSCs to regenerate tissues remains questionable, the Mesoblasts approach hinges on a body of evidence showing that MSCs can suppress inflammation and mobilize endogenous repair mechanisms through indirect effects on immune cells.

Indeed, the first-ever approved stem cell therapy, Prochymal, also depends on this mechanism. Prochymal was developed by US-based Osiris Therapeutics and in 2012 received Canadian approval to treat acute GvHD. But after Sanofi opted to shelve its partnership with Osiris prior to FDA approval, the biotech sold out its off-the-shelf stem cell platform to Mesoblast in a $100M deal.

In Belgium, companies like TiGenix and Promethera are also banking on the immunomodulatory properties of MSCs. The companies are developing treatments for patients with Crohns disease and liver diseases, respectively.

The ultimate hope for stem cell therapies has been to regenerate damaged or diseased tissues as found in diabetes, heart failure or blindness. Holostem Terapie Avanzate, a spin-off from the University of Modena and Reggio Emilia was the first company to move towards this goal.

Building on 20 long years of research, the biotech has developed Holoclar, the first and only autologous stem cell therapy (apart from bone marrow transplants) to enter the European market. Holoclar is based on limbal stem cells, located in a part of the eye called the limbus, which can be used to restore eyesight in patients that have lost sight due to burn injuries.

Meanwhile, UK-based Reneuron is developing off-the-shelf therapies that aim to restore the cognitive function of patients following a stroke. Backed by no other than Neil Woodford, the company recently raised an impressive 100M to advance its lead therapy to the market.

The biotechs fetal-derived neural stem cell line CTX was able to significantly reduce the disability of post-stroke patients in a Phase II trial and ReNeuron is now planning to push its candidate into pivotal trials.

A major question in the space a decade ago was safety. Today, theres been a lot of trials done that show that safety is not an issue. I think safety is kind of off the table but efficacy is still a question mark. And thats what were trying to deliver now, Olav Helleb, CEO of ReNeuron, told me.

While neural stem cells and other tissue-specific stem cells are able to regenerate the cells of a particular tissue, Embryonic Stem Cells (ESCs) and their engineered counterparts, iPSCs, are capable of making every cell type in the body, a property known as pluripotency. Pluripotent stem cells can also expand indefinitely in culture and their identification unlocked massive expectations for these cells to transform the regenerative medicine field.

Yet, these cells come with significant challenges associated with the safety of the final preparation. Apart from ethical issues surrounding ESCs, today, a lot of companies have been cautious about using these cells for therapy, because undifferentiated pluripotent cells can drive tumor formation, explained Rawadi. Since ESCs can, in principle, form every cell type, they can lead to the formation of teratomas.

A major reason for the fairly slow progress in the field is based on the difficulties of directing a pluripotent cell to exactly the cell type that is needed for cell therapy. We can readily drive the cells from the undifferentiated state to the differentiated state. However, getting those cells to pause anywhere in the middle of this continuum to yield progenitor cells is incredibly challenging, Peyer explained. Another challenge, he says, is to engraft the cells in the right place to enable them to become fully integrated.

Besides initial hurdles, companies like US-based Asterias or ViaCyte are now running the first Phase I/II trials with ESC-derived cells to treat patients with spinal cord injuries and to restore the beta cells in type I diabetes. So far, the eye has been the the dominant organ for many of the first human clinical trials with pluripotent stem cells, where the cells are assessed in diseases such as age-related macular degeneration (AMD) to restore the loss of the retinal epithelium.

Deriving retinal epithelium from pluripotent cells is relatively easy and in fact, researchers in Japan are now running the very first clinical trial using donor-derived iPSCs to treat patients with AMD. For reasons of safety and standardization, the trial is based on an allogeneic approach. However, since this doesnt offer an exact genetic match, allogeneic therapies raise the prospect of immune rejection, an issue that has been plaguing the use of ESCs.

But the scientists in Japan have contended that iPSC banks could potentially solve this problem. The team in Japan is currently establishing an iPSC bank, consisting of HLA-characterized cell lines from 5-10 different donors, which should match 3050% of Japans population.

Such haplobanks have the benefits of allogeneic cell therapy, namely cost-effectiveness and standardization, but you still have matching immune systems, Peyer agrees.

For now, this remains a vision for the future, but the potential seems enormous. As Julian Howell, CMO of ReNeuron, told me, iPSCs have still got an awful long way to go. For the iPSC program running in Japan, they recently acknowledged that it took about $1.5M and 6 months to treat each patient. Its a great idea but its still got some way to go before it reaches the scale that could get into the clinic.

Images via nobeastsofierce,Natali_ Mis,vchal/ Shutterstock

Read more here:
Regenerating the Body With Stem Cells Hype or Hope? - Labiotech.eu (blog)

Read More...

A brief look at the medical issues in the Charlie Gard case – ABC News

July 11th, 2017 9:46 am

Charlie Gard is a terminally ill British child whose parents are fighting for the right to take him to the United States for an experimental treatment. His case has gained international attention, including from Pope Francis and U.S. President Donald Trump.

The 11-month-old is being treated at London's Great Ormond Street Hospital, which maintained the experimental treatment was "unjustified" and might cause Charlie more suffering without doing anything to help him. The hospital planned to take the boy off life support, but petitioned for a new court hearing based on evidence from researchers at the Vatican's children's hospital and another facility outside of Britain.

Below is some background on the medical and legal issues behind Charlie's case:

WHAT IS MITOCHONDRIAL DISEASE?

Mitochondrial disease is the umbrella term for a number of rare conditions caused by genetic mutations that result in the failure of mitochondria, specialized compartments within most cells that supply the energy needed to sustain life and support organ function. When mitochondria fail, cells can be injured or die, causing organ systems to shut down. The brain, heart, muscles and lungs are most affected because they need the most energy.

Charlie suffers from a form of the disease known as infantile onset encephalomyopathic mitochondrial DNA depletion syndrome (MDDS.) It is specifically known as the RRM2B mutation of MDDS. There is no known cure.

WHAT IS THE TREATMENT HIS PARENTS WANT FOR CHARLIE?

Doctors in the United States have been experimenting with a treatment known as nucleoside therapy, which has shown success in reducing the symptoms of some types of mitochondrial disease in laboratory mice. The treatment has been administered to a small number of children who have also shown improvement.

However, the treatment has never been used on either mice or humans with the type of mitochondrial disease from which Charlie suffers, according to court documents.

HAS THE NUCLEOSIDE THERAPY BEEN USED BEFORE?

A boy named Arturito Estopinan in Baltimore was the first child to be given deoxynucleotide monophosphate, an experimental treatment that significantly extended the life of mice with the same condition as Arturito, known as TK2-related mitochondrial depletion syndrome.

Art Estopinan, the boy's father, met with Charlie's parents in London to share his experience. He stressed that while the therapy was a treatment, not a cure, his 6-year-old son was "getting stronger every day." Arturito still needs around the clock care. Estopinan and his wife, Olga, have given their lives over to caring for him, hoping that a cure will come one day. The sacrifices keep coming because "we love our son," he said.

"A lot of very smart doctors are unaware of these experimental medications," Estopinan said. "As a father, I cannot sit back and know that my son was saved and not be vocal in support of Charlie Gard receiving these meds."

A CRUEL DISEASE

Sian Harding, Director of the British Heart Foundation Cardiovascular Regenerative Medicine Center at Imperial College, described the difficulty of treating the disease that Charlie has.

"Mitochondrial diseases are cruel because they strike babies and young children, who rapidly deteriorate," Harding said. "It is because there is no cure that the scientific and medical community have concentrated on pre-conception mitochondrial therapy, and it has been an enormous advance that this is now licensed by the government. It allows parents with these mutations to have healthy children, though sadly, cannot help babies already born."

WHY IS IT UP TO THE COURTS AND NOT CHARLIE'S PARENTS?

Parents in Britain do not have the absolute right to make decisions for their children. It is normal for courts to intervene when parents and doctors disagree on the treatment of a child. The rights of the child take primacy, with the courts weighing issues such as whether a child is suffering and how much benefit a proposed treatment might produce.

Professor Dominic Wilkinson, director of medical ethics at the Oxford Uehiro Center for Practical Ethics, said decisions about life-sustaining treatment for a child are "fraught."

"Sadly, reluctantly, doctors and judges are justified in concluding that continuing life support is not always helpful for a child and is in fact doing more harm than good," Wilkinson said. "Providing comfort, avoiding painful and unhelpful medical treatments, supporting the child and family for their remaining time: sometimes that is the best that we can do, and the only ethical course."

Go here to see the original:
A brief look at the medical issues in the Charlie Gard case - ABC News

Read More...

Genetically modified food is too advanced for its out-of-date regulations – The Hill (blog)

July 11th, 2017 9:46 am

Last week, the USDA published a series ofquestionsseeking input to establish a National Bioengineered Food Disclosure Standard, as mandated by amendments to the Agricultural Marketing Act of 1946 that went into effect in July 2016.

TheNational Bioengineered Food Disclosure Standard Actrequires the Secretary of the Department of Agriculture to establish disclosure standards for bioengineered food. The Act preempts state-based labeling laws for genetically modified organisms (GMOs), such as those adopted inVermontlast year.

The USDA is considering public input on the disclosure standards untilJuly 17, 2017. Two key issues are under consideration. The first is whether certain genetic modifications should be treated as though they are found in nature for example, a mutation that naturally confers disease resistance in a crop. The second concerns what types of breeding techniques should be classified as conventional breeding among "conventional breeding" techniques are hybridization and the use of chemicals or radiation to introduce random genetic mutations.

These seemingly mundane questions strike at the heart of GMO controversies and implicate the use of breakthrough CRISPR gene editing technologies. Gene editing allows novel and precise genetic modifications to be introduced into crops and animals intended for human consumption. The answers to the USDA's questions are significant because the Disclosure Standard Act exempts from mandatory disclosure genetic modifications obtained without recombinant DNA (rDNA) techniques that can otherwise be found in nature.

However, CRISPR gene editing need not rely on using any foreign DNA and can introduce genetic modifications that mirror those already found in nature. Unlike rDNA and conventional breeding methods, CRISPR technologies introduce genetic changes with far greater accuracy and precision.

In 2016, the USDAdeclined to regulatetwo CRISPR crops a mushroom and a waxy corn under regulations governing traditionalGMOs. But other regulatory agencies, including the FDA and EPA, have not yet made determinations on crops or animals modified with CRISPR technology, and uncertainty looms concerning the regulatory status of this new breed ofGMOs.

Opponents ofGMOs, who commonly argue thatGMOsare harmful to human health, decried the USDA's decision not to regulate CRISPR crops and argued thatpowerful corporations had found ways to circumvent the law through technical loopholes in outdated regulations.

Yet three decades of scientific research suggest that present-dayGMOcontroversies are not grounded in scientific fact. For instance, despite frequent rumors aboutGMO-induced cancers, a scientific consensus has now formed to support the health and environmental safety of genetically modified crops for animal and human consumption. That proposition is supported by investigations of theU.S. National Academies of Science, Engineering, and Medicineas well as scientific panels including the American Association for the Advancement of Science, the American Medical Association, the European Commission, and National Academies of Science in Australia, Brazil, China, France, Germany, India, the United Kingdom, and other countries.

In its rulemaking process, the USDA should rely upon science and facts. With regard to crops and animals with DNA altered through gene editing, rulemakers ought to distinguish among ways that CRISPR technology may be used to edit genes. For instance, CRISPR technology can be used as a DNA construct that is incorporated into the DNA of plant or animal cells, or as a preassembled RNA and protein complex.

How gene editing is carried out matters, because some methods appear to fall within the disclosure requirements while others do not. The law definesbioengineered foodas food that contains genetic material modified through in vitro rDNA techniques. Thus, under the Disclosure Standard Acts statutory constraints, CRISPR food created using DNA constructs that are incorporated into plant or animal cells would likely fall under the mandatory disclosures.

However, food derived from rDNA-free CRISPR gene editing using transient preassembled RNA and protein complexes should be excluded from the bioengineered food definition because such complexes are degraded shortly after gene editing takes place and do not insert themselves into the target organism DNA.

The nuances of ever-evolving biotechnological innovation highlight the complexity of our regulatory system and the need to modernize it. The National Bioengineered Food Disclosure Standard Act is just one of the latest pieces of that regulatory patchwork to emerge. Rules establishing bioengineered food disclosures should be coherent and science-based. Gene editing that uses no foreign DNA, is more precise than conventional breeding methods, and causes genetic modifications already found in nature should not be subject to onerous disclosure standards.

Paul Enrquez is a lawyer and scientist currently doing research in Structural & Molecular Biochemistry at North Carolina State University. His work focuses on the intersection of science and law and has been featured in both legal and scientific journals. He explores rising legal and regulatory issues concerning genome editing in crop production in depth and makes policy recommendations in his recently published article CRISPRGMOs.

The views expressed by contributors are their own and not the views of The Hill.

See the original post here:
Genetically modified food is too advanced for its out-of-date regulations - The Hill (blog)

Read More...

Combivent coupon – Is combivent and albuterol the same – Van Wert independent

July 11th, 2017 9:46 am

Submitted information

OHIO CITY The Ohio City Park Association and the Lambert Days Committee has finalized plans for the 2017 festival.

Lambert Days is always the third full weekend in July. This years dates are July 21-23. This is also the 50th anniversary of Ohio Citys celebration of the life of John W. Lambert and his invention of Americas first automobile.

This years edition of Lambert Days will feature a communitywide garage sale. For more information, contact Laura Morgan at 419.965.2515. There will also be food all weekend in the newly renovated Community Building on Ohio 118.

Friday, July 21

Festivities start off with a steak dinner (carryout is available), starting at 4 p.m. Friday. Ohio Citys American LegionHarvey Lewis Post 346 will have aflag-raising ceremony at 5 Friday evening, while kids games and inflatables will also open at 5. At 6 p.m., the Lambert Days Wiffleball Homerun Derby will take place. For more information, contactLorenzo Frye 419.771.7037.

There will also be entertainment at 6 p.m. featuring Cass Blue. At 7, there will be a adult Wiffleball tournament. For more information, contact Brian Bassett419.203.8203. A Texas Hold em Tournament will begin at 7 p.m. Friday, along with Monte Carlo Night, which begins at 8 p.m. For more information, contact Jeff Agler at 419.513.0580.

Entertainment for Friday night starts at 8 and will be the band Colt & Crew. There will also be a fireworks display at 10:15 p.m. Friday (Saturday night is the rain date).

Saturday, July 22

Saturday morning begins with a softball tournament at 8. For more information, contact Brian Bassettat 419.203.8203. There will also be a coed volleyball tournament that starts at 9 a.m. Saturday. For more information, contact Tim Matthews at 419.203.2976. The Lambert Days Kids Wiffleball Tournament starts at 10 a.m. Saturday. For more information, contact Lorenzo Frye at 419.771.7037.

Kids games and Inflatables continue at 11 Saturday morning. Cornhole tournament registration and 3-on-3 basketball tournament registration start at noon, while both tournaments begin at 1 p.m. For more information on cornhole, contact Josh Agler at 567.259.9941 and for 3-on-3 basketball, contact Scott Bigham at 419.953.9511.

The Hog Roast Dinner starts at 4 p.m. Saturday and carryout is available. There will also be music under the tent by Jeff Unterbrink at 4. Bingo will start at 5 p.m., and the night ends with entertainment by Megan White and Cadillac Ranch.

(more)

The rest is here:
Combivent coupon - Is combivent and albuterol the same - Van Wert independent

Read More...

Christchurch MS patient Andrea Cameron-Hill plans Russia trip for stem cell treatment – The Press

July 11th, 2017 9:46 am

JOEL INESON

Last updated14:01, July 9 2017

IAIN MCGREGOR/Stuff.co.nz

Andrea Cameron-Hill has lived with multiple sclerosis for about 10 years. She wants to receive treatment in Russia that could stop the disease.

Andrea Cameron-Hill thought having to lift her leg to get in the carwhile pregnant was part of carrying twins.

About 10 weeks after they were born she learned she had multiple sclerosis (MS).

"To start with, you wouldn't know I had MS at all. But now it's 10 years on and I'm having to walk with a crutch," she said.

IAIN MCGREGOR/STUFF

MS sufferer Cameron-Hill wants to receive treatment that could stop the disease in its tracks but, despite it being offered here to treat some cancer, must travel to Russia to get it.

"If I have to go down to the floor to load the fire with wood, the difficulty for me now is getting off the floor."

READ MORE: *Multiple sclerosis sufferer Royce Brewer cleared after experimental treatment in Russia *Multiple sclerosis patient to receive 'experimental' treatment in Russia *Friends rallying to help Upper Hutt woman reach Mexico for stem cell treatment *Marlborough woman's search for cure *Plea to help fund stem-cell treatment for Andrea Campbell *Hunt after cure for MS disease

Cameron-Hill has injured her shoulder fromfalls and reliedon her husband, Paul, and sons Lachlanand Oliverto help with household chores.

IAIN MCGREGOR/STUFF

Normal household chores like washing are a challenge because of the debilitating condition.

She wanted to do things like go onto the rugby field while her childrenplayed, but MS meant she had to watch from the car.

"We've got a basketball hoop [at home], which they quite like playing, but they normally play with Grandma because I can't."

"I feel like a spectator in their lives. I hate it. I hate it with a passion."

IAIN MCGREGOR/STUFF

Cameron-Hill's sons, Lachlan and Oliver, pictured, help her complete tasks many do effortlessly.

Cameron-Hill's condition drove herto look at a treatmentused in New Zealand for some forms of cancer, but not available for MS.

She plans to head to Russia for undergohematopoieticstem cell transplantation (HSCT).

HSCT would remove, purifyand concentrate her stem cells.Chemotherapy would wipeher immune system before the stem cells were returned. An extended period of recovery would follow.

IAIN MCGREGOR/STUFF

Cameron-Hill wants to take part in her children's lives, rather than watch from the sidelines.

Cameron-Hill mustraise about $80,000 to get the treatment.So far about $10,000 has been raised through fundraising events and aGivealittlepage.

Leading New Zealand neurologist Dr Deborah Mason said HSCT wasunlikely to be trialledin New Zealand because it wouldnot make drug companies money.

Treatment for MSin New Zealandreliesonimmunosuppressantdrugs.HSCTwaslikened more to a surgical procedure than drug treatment.

"It's incredibly expensive ... We're very keen to participate in [trials and research] and I'd certainly enroll patients, but it's just finding somebody who would fund that, and nobody will because there's no drug involved," Mason said.

Mason saidHSCT might help young patients in the early stages of MS.

She said the treatment was "unproven" and came with risks.

"It's really hard to imagine why I get all these calls about bone marrow transplants ... all bone marrow transplant allows us to [do is] give industrial doses of chemotherapy."

"People talk aboutrebootingthe immune system and all of that. There isn't a lot of proof of that."

Mason knew of about six or seven people who had travelled forHSCT, but did not have a lot of follow-updata.

Studies and clinical trials New Zealanders took part in primarily focussed on medication.

Her "big beef" was with the government not allowing the use of some drugs, "which we absolutely know will benefit the patients".

The Multiple Sclerosis Society of New Zealand recently changed its standpoint on HSCTafter a report indicated the treatment workedfor some with MS in Australia and the UK.

Vice president Neil Woodhams said the group asked the Ministry of Health to start a process to lead to eligible people havingHSCTin New Zealand.

Cameron-Hill's MS had not progressed since 2013and she had not been on medication for it since.

She recently met Christchurch manRoyce Brewer who lived with MS for about 20 years. After undergoing HSCT in Russia in early 2016, hereturned to work as a landscaper at the end of the year.

"I'd just really love to be able to do ... normal stuff that parents do with their kids," Cameron-Hill said.

The Health Research Council of New Zealandhad not funded any research regarding MS andHSCT, a spokeswoman said.

-Stuff

Follow this link:
Christchurch MS patient Andrea Cameron-Hill plans Russia trip for stem cell treatment - The Press

Read More...

Experts call for global action on unproven stem cell therapies – BioNews

July 11th, 2017 9:46 am

International experts are calling for global action on unproven and potentially dangerous stem cell therapies, and their misleading marketing to the public.

'Many patients feel that potential cures are being held back by red tape and lengthy approval processes. Although this can be frustrating, these procedures are there to protect patients from undergoing needless treatments that could put their lives at risk,' said Dr Sarah Chan from the University of Edinburgh. She is one of 15 authors who published the clarion call in the journal Science Translational Medicine.

Currently only few conditions can be successfully treated with stem cells, including blood cancers, some immune diseases, and severe burns.

Despite this, unlicensed clinics advertise stem cell-based treatments directly to patients promising a cure for various ailments when there is no evidence to show they will help, or that they will not cause harm.

The internet and social media have helped the burgeoning direct-to-consumer marketing of both licensed and unlicensed stem cell therapies, and 'offers sellers the ability to reach worldwide audiences, amplifying the difficulties of enforcing national laws in a global marketplace', note the authors.

They add that patients are vulnerable to these online marketing strategies due to the hyped media coverage of stem cell research; a lack of reliable information; and a combination of missing international guidelines and conflicting national regulations on procedures.

Foregoing alternative therapies, patients take risks on invalid stem cell-based procedures, which have led to deaths in Australia, Russia and Germany, warn the authors. While those who sell the treatments may be difficult to hold accountable due to legal grey areas on stem cell-based treatments in most countries.

In addition to the potential harm to patients, 'unfulfilled promises may bring regenerative medicine research and development into disrepute' the authors caution.

In their call for action, the experts from UK, the USA, Canada, Belgium, Italy and Japan urge for a cooperation of national and international efforts to control the global industry of stem cell-based medical procedures and their advertising.

The authors believe that 'predatory' clinics can be exposed on a national level, when scientific experts, investigative journalists and local authorities work together, such as in a recent trial of the Stamina Foundation in Italy, a highly publicized provider of unproven stem cell treatments (see BioNews 878).

They further suggest controls on advertising and international standards for the manufacture and testing of cell and tissue-based therapies, similar to global drug quality standards, which might be set by the World Health Organisation.

Such measures will only be effective when national governing bodies cooperate to ensure compliance, but the experts warn that 'the stakes are too high not to take a united stance'.

View original post here:
Experts call for global action on unproven stem cell therapies - BioNews

Read More...

Trump supporters know Trump lies. They just don’t care. – Vox

July 11th, 2017 9:46 am

During the campaign and into his presidency Donald Trump repeatedly exaggerated and distorted crime statistics. Decades of progress made in bringing down crime are now being reversed, he asserted in his dark speech at the Republican National Convention in July 2016. But the data here is unambiguous: FBI statistics show crime has been going down for decades.

CNNs Jake Tapper confronted Trumps then-campaign manager, Paul Manafort, right before the speech. How can the Republicans make the argument that somehow its more dangerous today, when the facts dont back that up? Tapper asked.

People dont feel safe in their neighborhoods, Manafort responded, and then dismissed the FBI as a credible source of data.

This type of exchange where a journalist fact-checks a powerful figure is an essential task of the news media. And for a long time, political scientists and psychologists have wondered: Do these fact checks matter in the minds of viewers, particularly those whose candidate is distorting the truth? Simple question. Not-so-simple answer.

In the past, the research has found that not only do facts fail to sway minds, but they can sometimes produce whats known as a backfire effect, leaving people even more stubborn and sure of their preexisting belief.

But theres new evidence on this question thats a bit more hopeful. It finds backfiring is rarer than originally thought and that fact-checks can make an impression on even the most ardent of Trump supporters.

But theres still a big problem: Trump supporters know their candidate lies, but that doesnt change how they feel about him. Which prompts a scary thought: Is this just a Trump phenomenon? Or can any charismatic politician get away with being called out on lies?

In 2010, political scientists Brendan Nyhan and Jason Reifler published one of the most talked about (and most pessimistic) findings in all of political psychology.

The study, conducted in the fall of 2005, split 130 participants into groups who read different versions of a news article about President George W. Bush defending his rationale for engaging in the Iraq War. One version merely summarized Bushs rationale There was a risk, a real risk, that Saddam Hussein would pass weapons or materials or information to terrorist networks. Another version of the article offered a correction that, no, there was not any evidence Saddam Hussein was stockpiling weapons of mass destruction.

The results were stunning: Staunch conservatives who saw the correction became more likely to believe Hussein had weapons of mass destruction. (In another experiment, the study found a backfire on a question about tax cuts. On other questions, like on stem cell research, there was no backfire.)

Backfire is a pretty radical claim if you think about it, Ethan Porter, a political scientist at George Washington University, says. Not only do attempts to correct information not sink in, but they can actually make conflicts even more intractable. It means earnest attempts to educate the public may actually making things worse. So in 2015, Porter and a colleague, Thomas Wood at the Ohio State University, set out to try to replicate the effect for a paper (which is currently undergoing peer review for publishing in the journal Political Behavior).

And among 8,100 participants and on the sort of political questions that tend to bring out hardline opinions Porter and Wood hardly found any evidence of backfire. (The one exception, interestingly, was the question of weapons of mass destruction in Iraq. But even on that, the backfire effect went away when they tweaked the wording of the question.)

Theres no evidence that backfire describes a common reflex of Americans when it comes to facts, Porter assures me. (Nyhan, for his part, never asserted that backfire was ubiquitous, just that it was a possible and particularly consequential result of fact-checking.)

Stories of failed replications in social psychology often grow ugly, with accusations of bullying and scientific misconduct flying in both directions. But in this story, researchers decided to team up to test the idea again.

The fact that Nyhan and Reiflers breakthrough study didnt replicate isnt a shocker. This happens all the time in science. One group of researchers publishes a breakthrough finding. Another lab tries to replicate it, and fails.

But instead of feuding, Nyhan, Reifler, Porter, and Wood came together to conduct a new study.

If you believe in social science, this is an ideal way to resolve a dispute, Porter says. If we can devise an experiment together, then the results are going to have something meaningful to say about our differing understandings of the world.

So the four researchers collaborated on two experiments with a wide range of people as subjects, including Trump and Hillary Clinton supporters.

The first experiment drew on Trumps exaggerations of crime statistics.

In the experiment, participants read one of five news articles. One was a control article about bird watching. Another just contained a summary of Trumps message without a correction. The third was an article that included a correction. The fourth included a correction, but then also a line of pushback from onetime Trump campaign manager Paul Manafort, who said the FBIs statistics were not to be trusted. The fifth included a line where Manafort really laid into the FBI, saying, "The FBI is certainly suspect these days after what they just did with Hillary Clinton.

The thinking here: If anyone should be able to incite a backfire effect among Trump supporters, its Trumps campaign director. Manafort gives Trump supporters cover. They can reject the correction and cite one of the most influential figures in the campaign. And if theres a time backfire ought to occur, its during a presidential campaign, when our political identities are fully activated.

But it didnt happen. On average, all the studys participants were more likely to accept the correction when they read it. Trump supporters were more hesitant to accept it than Clinton supporters. But thats not backfire; thats reluctance. Manaforts assertion that the FBI statistics were not to be trusted didnt make much of a difference either.

Everyones beliefs about changing crime over the last 10 years became more accurate in the face of a correction, Nyhan says.

The research group then conducted a second experiment during the presidential debates. This one was conducted in near-real time: On the night of the first presidential debate, the group ran an online study with 1,500-plus participants.

The study focused on one Trump claim in particular. Trump said thousands of jobs [are] leaving Michigan, Ohio ... theyre just gone.

This, again, isnt true. The Bureau of Labor Statistics actually finds both states created 70,000 new jobs in the previous year. Half of the participants saw the correction; the other half did not.

Again, the researchers found no evidence of backfire. Its worth underscoring: This was on the night of the first presidential debate. Its the Super Bowl of presidential politics. If corrections arent going to backfire during a debate, when will they?

In both experiments, the researchers couldnt find instance of backfire. Instead, they found that corrections did what they were intended to do: nudge people toward the truth. Trump supporters were more resistant to the nudge, but they were nudged all the same.

But heres the kicker: The corrections didnt change their feelings about Trump (when participants in the corrections conditions were compared with controls).

People were willing to say Trump was wrong, but it didnt have much of an effect on what they felt about him, Nyhan says.

So facts make an impression. They just dont matter for our decision-making, which is a conclusion thats abundant in psychology science.

(And if youre thinking, How could one short experimental manipulation really change how much participants like Trump? know that other research shows its possible. Notably, studies conducted during the election found that just reminding white voters they may be a racial minority one day increased support for Trump.)

The big question is: To what extent do those results generalize beyond Trump himself? says Nyhan. Many of his supporters may have to come to terms with his records of misstatements by the time this study was conducted. (The researchers did not test any fact-checks of Hillary Clinton talking points.)

Nyhan doesnt place blame on Trump supporters themselves; its just human nature to stand by our political partys candidates. But he says theres something wrong with our institutions, norms, and party leaders who enable the rise of candidates who constantly lie.

At least its nice to know that facts do make an impression, right? On the other hand, we tend to avoid confronting facts that run hostile to our political allegiances. Getting partisans to confront facts might be easy in the context of an online experiment. Its much harder to do in the real world.

These results have not yet been peer-reviewed or published in an academic journal so treat them as preliminary. But I did run them by several political science and psychology researchers for a sniff test.

These two experiments are well done, and the data analysis appears to straightforward and correct: we observe clear movement on subjects beliefs as a result of factual corrections, Alex Coppock, who researches political decision-making at Yale, writes in an email. This piece is nice because it adds to the (small but growing) consensus that backfire effects, if they exist at all, are rare.

Others commended the researchers for collaborating in the face of conflicting results. I think this is exactly how the scientific process should operate as we try to explain human behavior, Asheley Landrum, who researches politically motivated reasoning at Texas Tech, writes. Social scientists, arguably, should be even more aware of motivated reasoning, recognizing that it also occurs in scientists.

Nyhans research is about seeing if attitude change is possible. And this research often comes to frustrating ends. In one study, he and Reifler tested out four different interventions to try to nudge vaccine skeptics away from their beliefs. None made a difference. Though it is elusive, at the least, he found a little attitude change within himself.

Jason [Reifler] and I have definitely updated our beliefs about the prevalence of the backfire effect, Nyhan says. He wont say its been debunked. But hes moving in that direction.

Go here to read the rest:
Trump supporters know Trump lies. They just don't care. - Vox

Read More...

The BEER that’s good for you – THIS alcoholic drink boosts gut health and immune system – Express.co.uk

July 10th, 2017 1:45 pm

Drinking beer could soon come with added health benefits, thanks to a team of researchers in Singapore.

A new speciality beer now includes the probiotic strain Lactobacillus paracasei L26, which was first taken from human intestines.

The bacteria has the ability to neutralise toxins and viruses and even boost the immune system, the scientists claim.

Studies have shown that eating food and drink with live counts of probiotics are more effective in delivering health effects than eating those with inactive probiotics.

GETTY

Recommendations by the International Scientific Association for Probiotics and Prebiotics is to have a minimum of 1 billion probiotics per serving in order to attain the maximum health benefits.

The idea of a probiotic beer was the brainchild of student Chan Mei Zhi Alcine, who consumes dairy-based probiotic drinks daily.

The health benefits of probiotics are well known, she said.

While good bacteria are often present in food that have been fermented, there are currently no beers in the market that contain probiotics.

Developing sufficient counts of live probiotics in beer is a challenging feat as beers contain hop acids that prevent the growth and survival of probiotics.

1 of 11

GETTY

Developing sufficient counts of live probiotics in beer is a challenging feat

Miss Chan said the recipe, which included the optimal count of live probiotics - took nine months to develop.

For this beer, we used a lactic acid bacterium as a probiotic micro-organism, she said.

It will utilise sugars present in the wort to produce sour-tasting lactic acid, resulting in a beer with sharp and tart flavours.

The final product, which takes around a month to brew, has an alcohol content of about 3.5 per cent, said Miss Chan.

GETTY

The NUS research team has filed a patent to protect the recipe for brewing the probiotic sour beer.

Associate Professor Liu Shao Quan from the NUS Food Science and Technology Programme said: The general health benefits associated with consuming food and beverages with probiotic strains have driven demand dramatically.

In recent years, consumption of craft or specialty beers has gained popularity too.

Alcines invention is placed in a unique position that caters to these two trends.

I am confident that the probiotic gut-friendly beer will be well-received by beer drinkers, as they can now enjoy their beers and be healthy.

Here is the original post:
The BEER that's good for you - THIS alcoholic drink boosts gut health and immune system - Express.co.uk

Read More...

Can Nutrition Boost the Equine Immune System? – TheHorse.com

July 10th, 2017 1:45 pm

TheHorse.com
Can Nutrition Boost the Equine Immune System?
TheHorse.com
The innate immune system is the general, first line of defense against pathogens (disease-causing organisms) or trauma. You're born with it, and it has no specificity or memory. The adaptive immune system learns to remember specific pathogens so it ...

Here is the original post:
Can Nutrition Boost the Equine Immune System? - TheHorse.com

Read More...

Can you really boost your mid-winter immune system? – Stuff.co.nz

July 10th, 2017 1:45 pm

LEE SUCKLING

Last updated05:00, July 6 2017

123RF

When it's not warm outside we often drink less water, but dehydration can lower the body's defences.

The middle of winter is here. No matter how healthy you think you are, the flu virus and various colds are abound and they're ready to infect your system.

There are some ways to boost your immune system and stay healthy for the rest of the chilly, virus-laden season, but a lot of what we think true is mythical.

First and foremost, hydration is key. When it's not warm outside we often drink less water, but dehydration can lower the body's defences. The eight glasses of water per day rule still rings true, however, an easier way to ensure you're never dehydrated is to look at the colour of your urine. If it's a pale yellow or clear, you're getting enough water.

While you're thinking about fluids, make sure you're drinking cow's milk. Milk is a good source of protein and also contains vitamins A and B12, which benefit your immune system. There's also milk's calcium factor, which you know keeps bones strong too.

READ MORE: *Any truth to common myths about being sick? *Three things you can do to avoid catching the flu at work *Manifesto: Unravelling the myth of the man flu

Owing to a lack of sun, our bodies can become vitamin D deficient in winter. You can consider taking a vitamin D3 supplement until the sun's rays come out again, though food sources such as fish, eggsand mushrooms do contain good doses of it.

Not only does the body not produce vitamin C by itself either, if you're physically or mentally stressed you require 20-40 times more of it to maintain optimal levels. This can't be neglected in winter, so it remains important to eat citrus fruits.

Having a good level of zinc in your body too (it comes from beef and lamb, nuts and seeds, and shellfish) may help shorten the length of the common cold. When combined with vitamin C, zinc is can also help heal scrapes and wounds faster.

Aside from these primary dietary interventions, your best bet in having a strong immune system throughout winter is to keep up (or increase) your exercise, and consume protein to repair your muscles. The immune system runs on protein, which is why the old wives' tale of chicken soup for generally illness is potentially true: chicken is high in protein, and the broth is a good source of fluids.

Some winter wellness old wives' tales are no more than myths, however. Echinacea was proven in Annals of Internal Medicine journal to be ineffective in preventing or treating colds. In this randomised controlled trial, there was no difference in health outcomes for those who took a placebo, or those who took no supplement at all. So-called "small preventative effects" of echinacea haven't been ruled out in other studies, but there's no good evidence to support them either.

Any other supplements that market themselves as beneficial for "immune system defence" (or similar) are also unlikely to be based on any science. There's very little evidence that any supplement can boost the chemical components of your immune system that system's repertoire is made up of thousands of genetic elements.

The vitamins and various other treatments from health stores that claim they can prevent or cure general coughs and colds are not backed up by solid proof. They may be helping specific parts of your system (e.g. boosting vitamin D, C, and zinc quantities), but cannot be relied on to improve your overall immune system during winter.

It's also important to understand that from a scientific point of view, there's also a big downside to having a seasonally-souped-up immune system.

Researchers from University of Cambridge found that while a seasonally-increased immune defence system helps fight off infections such as colds and the flu, it also raises inflammation in the body. The study found that the immune system's activity boosts during winter to stave off infections and relaxes during summer when it is less needed.

Unfortunately, what this winter boost of inflammation does is raise your risk of heart attacks, stroke, severe cases of depression and other mental health disorders, and Alzheimer's disease. Generally, as these Cambridge scientists suggest, the enhanced risk factor for disease when one's immune system is seasonally-boosted may outweigh the benefits of being able to fight off less serious colds and influenza viruses.

* Lee Suckling has a masters degree specialising in personal health reporting. Do you have a health topic you'd like Lee to investigate? Send us an email to life.style@fairfaxmedia.co.nz with Dear Lee in the subject line.

-Stuff

Read more:
Can you really boost your mid-winter immune system? - Stuff.co.nz

Read More...

Experts Call for Tighter Regulation of Stem Cell Therapies in Use at Clinics Worldwide – Multiple Sclerosis News Today

July 10th, 2017 1:43 pm

Advertising forstem cell therapies not supported by clinical researchoftenmadedirectly to patients and sometimes promoted as a cure for diseases like multiple sclerosis or Parkinsons is a growing problem that needs to be addressed and regulated, a team of leading experts say, calling suchstem cell tourism potentially unsafe.

Stem cell tourism is the unflattering name given to the practice of encouragingpatients totravel outside their home country to undergo suchtreatment, typicaly at a private clinic.

The article, titledMarketing of unproven stem cellbased interventions: A call to actionandrecently published inthe journal Science Translational Medicine, was co-authored by scientistswith universities and hospitals in the U.S., Canada, U.K., Belgium, Italy, Japan, and Australia. It focuses on the global problem of thecommercial promotion of stem cell therapies and ongoing resistance to regulatory efforts.

Its authors suggest that a coordinated approach, at national and international levels, be focused on engagement, harmonization, and enforcement in order to reduce risks associated with direct-to-consumer marketing of unproven stem cell treatments.

Treatments involving stem cell transplants are now being offered by hundreds of medical institutions worldwide, claiming efficacy in repairing tissue damaged by degenerative disorders like MS, even thoughthose claim often lack or are supported bylittle evidence .

They alsonoted that the continued availability of these treatments undermines the development of rigorously tested therapies, and potentially canendanger a patients life.

The researchers emphasizethat tighter regulations on stem cell therapy advertising are needed, especiallyregarding potential clinical benefits. They support the establishment ofinternational regulatory standards for the manufacture and testing of human cell and tissue-based therapies.

Many patients feel that potential cures are being held back by red tape and lengthy approval processes. Although this can be frustrating, these procedures are there to protect patients from undergoing needless treatments that could put their lives at risk, Sarah Chan, a University of Edinburgh Chancellors Fellow and report co-author, saidin anews release.

Chan and her colleagues are also calling for the World Health Organization to offer guidance on responsible clinical use of cells and tissues, as it does for medicines and medical devices.

Stem cell therapies hold a lot of promise, Chan said, but we need rigorous clinical trials and regulatory processes to determine whether a proposed treatment is safe, effective and better than existing treatments.

According to the release, the report and its recommendationsfollowed the death of two children at a German clinic in 2010. The clinichas since been shut down.

Certainstem cell therapies mostly involving blood and skin stem cells have undergone rigorous testing in clinical trials, the researchers noted. A number of theseresulted in aprovedtreatments for certain blood cancers, and to grow skin grafts for patients with severe burns.

Information about the current status of stem cell research andpotential uses of stem cell therapiesis availableon the websiteEuroStemCell.

Visit link:
Experts Call for Tighter Regulation of Stem Cell Therapies in Use at Clinics Worldwide - Multiple Sclerosis News Today

Read More...

Researchers Create ‘Heart Cells in a Dish’ to Study FA Heart Disease – Friedreich’s Ataxia News

July 10th, 2017 1:43 pm

Australian researchers have successfully turned stem cells from Friedreichs ataxia (FA) patients into heart cells to study molecular anomalies that maycontribute to this disease.

Theseheart cells in a dish provide valuable information for the design of novel treatments.

Their study, Friedreichs ataxia induced pluripotent stem cell-derived cardiomyocytes display electrophysiological abnormalities and calcium handling deficiency. appearedin the journal Aging.

FAis caused by low levels of the frataxin protein due to anomalies in the gene sequence encoding this protein repeats of DNA portions within the gene. The higher the number of repeats, the sooner the onset of FAand its associated complications.

Frataxin plays an important role in the mitochondria, the cells powerhouse, so the mutated protein accounts for several symptoms that reflect deficiencies in energy production. The heart is one of the organs affected by this lack of energy.

Cardiomyopathy is detected in two-thirds of individuals with FRDA[Friedreichs ataxia], researchers wrote. Individuals with FRDA generally present with progressive cardiomyopathy of the left ventricle, which is the leading cause of death in FRDA due to arrhythmias and/or heart failure.

Previous studies have shown that death of heart cells, or cardiomyocytes, and fibrosis may contribute to heart complications in FA, but little is known about the diseases impact on the heart.

Researchers generated stem cell cultures using cells from three FA patients with heart complications. They then stimulated the development of these stem cells into cardiomyocytes basically, heart cells in a dish.

The new cardiomyocytes had low levels of frataxin, as expected, but alsoabnormal ionic currents, which are crucial for the normal functioning of these cells. They also had morevariation in their beating rates, which was linked todeficient calcium control, ultimately affecting howthe cardiomyocytes work.

Together, these results pave the way for understanding how FA patients develop abnormal heart activity as well as theuse of induced stem cells to studycardiomyopathy within the context of this disease.

Importantly, our data clearly indicates that FRDA iPSC [stem cells]- derivedcardiomyocytes can be used for screening of compounds able to alter or reverse phenotypes, in human cells, hence providing a novel and unique tool for FRDAresearch, researchers concluded.

More here:
Researchers Create 'Heart Cells in a Dish' to Study FA Heart Disease - Friedreich's Ataxia News

Read More...

BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy … – PR Newswire (press release)

July 10th, 2017 1:43 pm

Up to 40 patients are planned to be enrolled in this Phase 1b/2, multicenter, randomized, controlled, open-label study to evaluate the clinical response, safety and tolerability, as well as multiple pharmacodynamic parameters, of BL-8040 in combination with atezolizumab. Initially, patients will receive BL-8040 injections as priming monotherapy for five consecutive days, after which, from day 8, they will receive both BL-8040 and atezolizumab, and continue with multiple treatment cycles for up to two years or until disease progression, clinical deterioration or unacceptable toxicity.

The clinical study collaboration between BioLineRx and Genentech, a member of the Roche Group, is part of MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to assess the efficacy and safety of combination cancer immunotherapies.

Philip Serlin, Chief Executive Officer of BioLineRx, stated, "We are very pleased with the launch of the first clinical study under our cancer immunotherapy collaboration with Genentech. Pancreatic cancer is a very difficult cancer to treat, and both conventional chemotherapy and immunotherapy have failed to demonstrate a significant benefit for these patients. BL-8040 has been shown to have robust mobilization of immune cells, improve the infiltration of T cells into solid tumors, and affect the immunosuppressive tumor micro-environment. We are therefore hopeful that combining atezolizumab with BL-8040 can lead to a significant advancement in the treatment of pancreatic cancer, and of other solid tumors that are difficult to treat. We look forward to the initiation of additional combination studies under this collaboration, all planned for the second half of this year."

BioLineRx is carrying out a larger cancer immunotherapy collaboration with Genentech to conduct several Phase 1b/2 studies investigating BL-8040 in combination with atezolizumab in multiple cancer indications, announced in September 2016.

BL-8040, BioLineRx's lead oncology platform, is a CXCR4 antagonist that has been shown in clinical trials to be a robust mobilizer of immune cells and to be effective in inducing direct tumor cell death. Additional findings suggest that BL-8040 may be effective in inducing the migration of anti-tumor T cells into the tumor micro-environment, as well as improving the infiltration of T cells into solid tumors. Atezolizumab is a humanized monoclonal antibody designed to bind to PD-L1 in tumor cells and tumor infiltrating immune cells and blocks interactions with the PD-1 and B7.1 receptors. Through this interaction, atezolizumab may enable the activation of T cells, whose migration into the tumor may be enhanced by BL-8040.

About BL-8040

BL-8040 is a short peptide for the treatment of acute myeloid leukemia, solid tumors, and stem cell mobilization. It functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a number of clinical and pre-clinical studies, BL-8040 has shown robust mobilization of cancer cells from the bone marrow, thereby sensitizing these cells to chemo- and bio-based anti-cancer therapy, as well as a direct anti-cancer effect by inducing cell death (apoptosis). In addition, BL-8040 has also demonstrated robust stem-cell mobilization, including the mobilization of colony-forming cells, T, B and NK cells. BL-8040 was licensed by BioLineRx from Biokine Therapeutics and was previously developed under the name BKT-140.

About BioLineRx

BioLineRx is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2a study for relapsed/refractory acute myeloid leukemia (AML), is in the midst of a Phase 2b study as an AML consolidation treatment, and is expected to initiate a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which is expected to initiate a first-in-man study in the first half of 2018. In addition, BioLineRx has a strategic collaboration with Novartis Pharma AG for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada), on the basis of which the Company has initiated a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA; and a collaboration agreement with Genentech Inc., a member of the Roche Group, to investigate the combination of BL-8040 and Genentech's TECENTRIQ in several Phase 1b/2 studies for multiple solid tumor indications and AML.

For additional information on BioLineRx, please visit the Company's website athttp://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated onFacebook,Twitter, andLinkedIn.

TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 23, 2017. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contacts: PCG Advisory Vivian Cervantes Investor Relations +1-212-554-5482 vivian@pcgadvisory.com

or

Tsipi Haitovsky Public Relations +972-52-989892 tsipihai5@gmail.com

SOURCE BioLineRx Ltd.

Continue reading here:
BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy ... - PR Newswire (press release)

Read More...

Risking her life to save it: Local woman tries stem cell transplant to control MS – WKYC-TV

July 10th, 2017 1:43 pm

Local woman trying experimental treatment to stop debilitating disease

Monica Robins, WKYC 12:11 AM. EDT July 06, 2017

(Photo: Submitted by Chelsea Jennings)

Chelsea Jennings uses yoga to stay centered. Its teaching keep her positive, which is important for for someone about to risk her live to save it.

She's only 26 and facing a rapidly progressing debilitating disease that will likely put her in a wheelchair within a year.

As a new mom, she won't accept that.

That's why she's risking her life for an experimental treatment that could possibly cure her disease.

Her motivation to try an experimental stem cell transplant to control her multiple sclerosis? Her 18-month-old son Camden and husband Jeff. "I understand that there is an extreme risk, but if the medication is not working for me I cannot just slowly deteriorate in front of my family, my son," Chelsea says. "I cannot have that happen."

Diagnosed five years ago, Chelsea tried every MS medication available, but couldn't tolerate them. She researched alternatives and found Dr. Richard Burt at Northwestern University who performs hematopoietic stem cell transplantation for MS. Last month, she went in for testing and was approved.

Unfortunately it's not covered by her insurance.

Undaunted, Chelsea held fundraisers to come up with the $125,000 dollar cost for a treatment with no guarantees. "Sometimes I do get scared and I do think, 'Well. what if I go through this whole thing and it doesn't work?' but I feel like I have to, " she explains. "I feel like I'm called to do this. This is my path, my journey."

This Friday, she'll receive chemotherapy to mobilize stem cells into her blood, then daily injections to boost the number. 10 days later, the cells will be collected and frozen. Chelsea will be able to come home for a couple of weeks before her next phase: more chemo to suppress her immune system and then receiving back her stem cells.

The hope is the new cells will regenerate the damage from MS.

But the treatment is not without consequences. There is a low chance of death from the procedure, plus she'll be at higher risk from illness initially and likely go into early menopause.

While considered experimental, this treatment has been studied for more than a decade.

Research shows 83 percent of patients stay in remission for two years post-transplant.

2017 WKYC-TV

Originally posted here:
Risking her life to save it: Local woman tries stem cell transplant to control MS - WKYC-TV

Read More...

News Bites: PPIs found to increase risk of early death, Mini colons in-a-dish could allow personalised drug testing – MIMS General News (Hong Kong)…

July 10th, 2017 1:43 pm

Mindnosis, developed by graduate designer Sara Lopez Ibanez, consists of a set of exercises that help understand emotional distress and how to feel better about it.

The first tool, named Discover, is made of six colourful triangles, whereby each represents a different area affecting the user's wellbeing. The triangles can be pasted into the Record journal along with daily thoughts and reflections.

The third element of the toolkit, named TryOut, is a set of eight activity cards that combine mindfulness, cognitive behaviour therapy techniques (CBT) and tips from peers to help users when they feel unwell.

Learn, is the fourth tool which comprises six small coloured cards that correspond with the Discover triangles briefly explaining the different issues, while a Crisis Help sheet has information about services and help lines.

Researchers say that their 3-D-printed heart valve models (shown here) could improve the outcomes of heart valve replacements. Photo credit: Rob Felt

In TAVR surgeries, paravalvular leakages are common especially when the prosthetic valve fails to achieve a precise fit within the patient's damaged aortic valve.

Therefore the Cardiovascular Imaging Research at Piedmont Heart Institute in Atlanta US, has developed 3-D heart valve models that could better predict the fit of a prosthetic valve.

The models were created to simulate the physiological properties of heart valve tissue using a variety of different synthetic materials. Prosthetic valves were then implanted in the 3-D models and through medical imaging and computer software, the team monitored the valves in the 3-D models.

A "bulge index" was then created to predict the severity of paravalvular leakage after undergoing TAVR; the greater the bulge index score, the higher their severity of paravalvular leakage.

The researchers looked at allergies that produce respiratory and skin symptoms including dust mites, cats and grass. The team gathered data from nearly 9,000 mother-child pairs in the Avon Longitudinal Study of Parent and Children, an ongoing research project that tracks the health of families with children born between 1 April 1991 and 31 December 1992.

The amount of free sugars consumed by women during pregnancy was based on self-reported estimates in questionnaires. The team also looked at how the mothers' sugar consumption compared with allergies and asthma diagnosed in the children beginning age of seven.

Approximately 22% of the children had a common allergy, 16% had eczema, 12% had asthma, 11% had wheezing with whistling and 9% developed hay fever.

Comparing with children whose mothers consumed the least sugar during pregnancy less than 34g per day the children of women with highest sugar intake during pregnancy had a 38% higher risk of allergy diagnosis. There was also a 73% increased risk of being diagnosed with an allergy to two or more allergens and the allergic asthma risk increased by 101%.

This is a human colon organoid, with colors showing signals also found in the natural human colon. Photo credit: Cincinnati Children's Hospital Medical Centre

The cells expressed several colon genes and to prove that their newly made human colon organoids were stable, they transplanted them into mice. The organoids continued to grow and mature in the mouse model.

What is also different in the team's work is that the stem cells can come from a simple blood draw and the method used, creates multiple cell types, so they could study how different cells interact within the complex layers of the colon. This could prove to be important when understanding diseases like colon cancer.

The team is now beginning to use the organoids to model inflammatory diseases such as ulcerative colitis and Crohn's disease. MIMS

Read more: News Bites: Microneedle patch could replace flu vaccines, Tick saliva could pave way for a range of new drugs News Bites: Preeclampsia may be linked to babies' DNA, Vaccine can lower "bad" cholesterol and heart attacks News Bites: Implanting pig cells into brains to slow down Parkinson's Disease, Aspirin may lower breast cancer risk

Sources: http://www.telegraph.co.uk/science/2017/07/03/heartburn-drugs-taken-millions-may-increase-risk-early-death/ https://www.dezeen.com/2017/07/04/mindnosis-kit-helps-people-overcome-mental-health-issues-graduate-designers-2017/ http://www.medicalnewstoday.com/articles/318193.php http://edition.cnn.com/2017/07/05/health/sugar-pregnancy-child-allergy-asthma-study/index.html https://www.statnews.com/2017/06/30/gut-organoids-medicine/

Read the original:
News Bites: PPIs found to increase risk of early death, Mini colons in-a-dish could allow personalised drug testing - MIMS General News (Hong Kong)...

Read More...

Is Inflammation the Key to Aging? – HuffPost

July 10th, 2017 1:42 pm

By Deepak Chopra, MD, William C Bushell, PhD, Ryan Castle, David Vago, PhD, Mark Lambert, Rudolph E. Tanzi, Ph.D.

Ten years ago researchers began to focus on inflammation as a link to disease. They stood out in that they did not emphasize the acute redness and swelling that accompanies the site of a wound or burn as it heals, which is known as acute inflammation. Rather, they discovered clues were leading to something more subtle a low-grade, chronic inflammation that has few if any overt symptoms. This kind of everyday inflammation has now been linked to an overwhelming majority of serious lifestyle disorders, including hypertension, heart disease, type 2 diabetes, Alzheimers disease and most cancers. What was an intriguing trend ten years ago is now being recognized as major global epidemic, all the more dangerous because it is invisible.

We encourage you to read the first post we wrote last week in order to gain more basic knowledge about chronic inflammation. Going past lifestyle disorders, chronic inflammation may be the key to aging. In addition, numerous inflammation-related genes have been linked to susceptibility to most age-related diseases, such as those mentioned above. The chemical markers in the bloodstream that serve to indicate inflammation are associated with the aging body and cellular death. Already some gerontologists are floating the idea that inflammation may be the largest contributor to aging. If this turns out to be right it will greatly simplify a complex subject, because two aspects of aging have traditionally made it very hard to grasp medically.

First, the deterioration of the body over time is not a straight line but an unpredictable set of changes that look different in everyone. Second, no single process can be pinned down as aging by itself. The common signs of aging, such as losing muscle strength, defects in memory, and moving more slowly - not to mention medical conditions like arthritis and dimmed eyesight are related to many different processes and don't appear in every elderly person. In fact, there are at least a few cases where these changes are at least temporarily reversed; there are even people who get stronger and have better memories as the years go by. Chronic inflammation has the possibility to simplify this scenario, in part by exploring the common factor that so many seemingly unrelated aging processes share.

Another connection with aging is centered on the immune system. When you were young, your immune system was very specific, precise, and targeted as it met invading pathogens (i.e., bacteria and viruses). This precision sets human beings apart from lower rungs on the evolutionary ladder where immunity is very general and diffuse. Instead of being precise, a diffuse immune system sends the same chemicals in various doses to spots of injury and disease. There is no precise targeting. As we age, our immune system loses the precision of youth, and because inflammation is the most general type of response to pathogens, the body begins to indiscriminately secrete inflammatory chemicals that injure its own cells rather than healing them. If this goes on long enough, damaging feedback loops are set up that turn diffuse immunity into a pattern. This exacerbates the damage to cells throughout your body, accelerating cellular death. This complex syndrome has been labeled "InflammAging." The glia cells in the brain that normally nurture and support nerve cells can instead attack nerve cells in bouts of neurology-inflammation.

Chronic inflammation takes years or even decades before visible damage or disease symptoms appear. This means that to reverse the process individuals must dedicate significant time. No one can do that without turning anti-inflammation into a lifestyle that feels as easy and natural as their present lifestyle. The most basic changes involve going down the list of things that create inflammation and doing the opposite instead. The result looks something like the following:

A balanced lifestyle without extreme changes.

A natural whole foods diet.

Paying attention to everyday activity, including walking and standing.

Absence of emotional upset, anxiety, and depression.

Solid family and community support.

Feeling loved and wanted.

A calm, unconflicted mind.

Nothing here is a surprise, but the distinction lies in understanding these changes are not just positive in some general way, they could literally save your life. It would appear that stress is extremely important because our response to everyday stress directly leads to stress on cells, and stressed cells produce the biochemicals that indicate inflammation. It is now well known that psychosocial stress may also significantly exacerbate many forms of disease pathology, including psychological disorders like anxiety and depression. Stress can actually produce chemicals that are toxic to nerve cells in the brain, such as cortisol. It has been theorized that the most serious form of depression, Major Depressive Disorder, could be considered an inflammatory disease.

This and other clues relate to aging, in that it takes smaller stresses to agitate older people, and they recover from them more slowly. What if this is the result of longstanding inflammatory feedback loops? There are numerous psychosocial causes for increase inflammation in the elderly, and there are age-specific types of depression. Being able to trace these conditions to a single cause would be very beneficial.

If stress and inflammation are the joint villains in aging and disease, the top priority in making lifestyle changes should be anti-stress. It is ironic that millions of people who willingly undertake improving their diet and exercise put a low priority on everyday stress, enduring routine pressures at home and work. In an exciting development, a growing body of literature has suggested systematic forms of mental training associated with meditation practice, good diet and sleep habits, and daily exercise, may improve clinical outcomes through an anti-inflammatory mechanism. It has been suggested previously that specific forms of meditation practice can indeed engage and modulate vagal tone through what has been coined, the relaxation response - a volitional state in which physiological recovery from psychosocial stress is facilitated. Much progress has been made in the last decade to identify potential neuroanatomical and network- based physiological changes due to mindfulness and other styles of meditation training.

We've outlined the main points of a new picture of aging and disease. Research is ongoing, and by no means do aging researchers all agree on inflammation as the root cause of aging. For one thing, inflammation, being necessary for the healing response, is a beneficial process as well as a harmful one, and discriminating between the two is complex. Second, the presence of inflammatory markers in the bloodstream, some would argue, is a symptom of stressed, dying cells, not the cause. However these issues resolve themselves in the future, the damaging effects of low-grade chronic stress are indisputable already. More in-depth research into the complex systems of the body and its inflammatory response are needed to determine these surprisingly fundamental questions.

A lifestyle aimed at countering inflammation has been described in detail in the book, Super Genes, and is a central part of the upcoming book by Deepak Chopra and Rudy E. Tanzi, The Healing Self. There you will find an in-depth discussion as well as a lifestyle program that addresses this vital topic.

Deepak Chopra MD, FACP, founder ofThe Chopra Foundationand co-founder of The Chopra Center for Wellbeing, is a world-renowned pioneer in integrative medicine and personal transformation, and is Board Certified in Internal Medicine, Endocrinology and Metabolism. He is a Fellow of the American College of Physicians and a member of the American Association of Clinical Endocrinologists. Chopra is the author of more than 80 books translated into over 43 languages, including numerous New York Times bestsellers. His latest books areSuper Genesco-authored with Rudy Tanzi, Ph.D. and Quantum Healing (Revised and Updated): Exploring the Frontiers of Mind/Body Medicine. http://www.deepakchopra.com

William C Bushell, PhD, Biophysical Anthropology, MIT is the Director of Research at ISHAR and has been researching mind-body phenomena for over three decades, focusing on the field of consciousness studies around the world as a biological, medical, and psychological anthropologist affiliated with Columbia, Harvard, and MIT.

Ryan Castle, Executive Director of ISHAR, specializes in research analysis and whole systems integration. He is an advocate for open-access science and multidisciplinary approaches.

David Vago, PhD, is Research Director of the Osher Center for Integrative Medicine at Vanderbilt University Medical Center; Associate professor, department of Physical Medicine & Rehabilitation; Associate professor, department of psychiatry and behavioral sciences; Research associate, Brigham & Women's Hospital, Harvard Medical School

Mark Lambert, Project Manager and Director of Innovation for the Center for Bioelectronic Medicine, Karolinska Institute, and supported Dr. Kevin Tracey as Chief of Staff for the Feinstein Institute for Medical Research.

Rudolph E. Tanzi, Ph.D. is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice Chair of Neurology at Mass. General Hospital. Dr. Tanzi is the co-author with Deepak Chopra of the New York Times bestseller, Super Brain, and an internationally acclaimed expert on Alzheimer disease. He was included in TIME Magazine's "TIME 100 Most Influential People in the World".

The Morning Email

Wake up to the day's most important news.

See the original post:
Is Inflammation the Key to Aging? - HuffPost

Read More...

Yoga proves to be effective treatment for chronic lower back pain – McKnight’s Senior Living

July 10th, 2017 1:42 pm

July 07, 2017

Yoga classes designed to address lower back pain produced results similar to physical therapy for people with chronic lower back pain, a Boston Medical Center study has found.

The large impact of chronic low back pain on suffering, disability and cost means we need to explore other treatment models that can offer relief, and our study indicates that yoga classes tailored to back pain patients may be a safe and effective option, said Robert Saper, M.D., MPH, study author, family physician and director of integrative medicine at BMC.

The study included 320 adults with chronic lower back pain. Participants were divided into two groups and were observed over a 12-week study period and a 40-week maintenance period.

Participants in the yoga group took a weekly class for the first period, and then they attended drop-in classes or practiced at home in the second period. Those in the physical therapy group went to 15 sessions in the first period, and then they went to booster sessions or did exercises at home for the second session.

After the three months of more intensive treatment and the nine more months of maintenance treatment, study participants in each treatment group expressed similar satisfaction with the treatment and their pain levels.

This study was published in the Annals of Internal Medicine.

The National Institute on Aging, part of the National Institutes of Health, has posted information about yoga and tips for older adults on its website.

Go here to see the original:
Yoga proves to be effective treatment for chronic lower back pain - McKnight's Senior Living

Read More...

Kiwanis Club of Clermont – The Clermont News Leader

July 10th, 2017 1:42 pm

Pictured: Dr. Mike Lewis, owner of Orlando Spine and Joint Integrated Medical Centers (left) and Aurelia Cole, President-Designate of the Kiwanis Club of Clermont

Dr. Mike Lewis, owner of Orlando Spine and Joint Integrated Medical Centers, was the guest speaker at the Kiwanis Club of Clermont on June 27, 2017. Dr. Lewis explained that Integrative Medicine (IM) is a healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. It emphasizes the therapeutic relationship between the physician and the patient and makes use of all appropriate therapies. Lewis practice has two locations, one in Clermont and another in Winter Haven, Florida. He talked about the latest technology and procedures and non-surgical options for treatment of musculoskeletal issues such as herniated discs, osteoarthritis, rotator cuff problems and many more conditions. Dr. Lewis said that Orlando Spine and Joint offers treatments such as non-surgical Spinal Decompression, Guided Joint Injections, Platelet Rich Plasma (PRP), Bone Marrow Stem Cells and many more. As a clinic that focuses on surgery avoidance and pain relief, he is excited about a new, non-surgical, minimally invasive, alternative that has helped thousands of individuals worldwide find lasting relief from their Osteoarthritis knee pain and that this same knee procedure can be applied to the shoulder and hip to help those who are looking for options other than surgery. For more information on these treatments please contact Dr. Lewis at (407) 614 5900. At the conclusion of his presentation, President Designate, Aurelia Cole, thanked Dr. Lewis for his very informative discussion.

Read this article:
Kiwanis Club of Clermont - The Clermont News Leader

Read More...

Page 966«..1020..965966967968..980990..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick